Educational Intervention for HER2+ or HER2 low Breast Cancer
This study is testing an educational program designed to improve how patients and doctors communicate about managing side effects from breast cancer treatments. Specifically, it focuses on patients with HER2-positive or HER2 low breast cancer who are receiving or about to start specific antibody drug conjugates (ADCs) like fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine. The program includes videos on shared decision-making (SDM) to help you and your doctor work together on your care. Researchers will measure if this education helps reduce decisional conflict (how unsure you feel about treatment decisions) at the start, 3 months, and 6 months into the study. The study is looking for 30 participants and its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive an intervention. It plans to enroll 30 participants.
- What's involved
- You would have 3 visits (which can be virtual) and complete survey information.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your decisional conflict will be measured at baseline, 3 months, and 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Breast Cancer Implementation Science Study With Educational Intervention
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nancy Chan, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Decisional Conflict Scale (DCS) ScoreBaseline
16-item assessment of a person's uncertainty in making a healthcare choice. Each item is rated on a 5-point Likert scale from 0 (strongly agree) to 4 (strongly disagree). The total score is the sum of responses and ranges from 0-64; lower scores indicate less uncertainty. Assessed among patients only.
- Decisional Conflict Scale (DCS) ScoreMonth 3
16-item assessment of a person's uncertainty in making a healthcare choice. Each item is rated on a 5-point Likert scale from 0 (strongly agree) to 4 (strongly disagree). The total score is the sum of responses and ranges from 0-64; lower scores indicate less uncertainty. Assessed among patients only.
- Decisional Conflict Scale (DCS) ScoreMonth 6
16-item assessment of a person's uncertainty in making a healthcare choice. Each item is rated on a 5-point Likert scale from 0 (strongly agree) to 4 (strongly disagree). The total score is the sum of responses and ranges from 0-64; lower scores indicate less uncertainty. Assessed among patients only.
- Patient HER2-Targeted ADC Related Side Effect Pre-Test ScoreBaseline
6 questions assessing ability to recognize HER2-targeted ADC-related AEs and how they are managed. 4 items are multiple choice questions with (1) correct answer. The final 2 items are rated on a Likert scale from 5 (Always) to 1 (Never). The score is calculated as the sum of (a) total correct answers to items 1-4 and (b) responses to items 5-6. The total score ranges from 2-14; higher scores indicate greater ability to recognize HER2-targeted ADC-related AEs and how they are managed.
- Patient HER2-Targeted ADC Related Side Effect Post-Test ScoreMonth 3
6 questions assessing ability to recognize HER2-targeted ADC-related AEs and how they are managed. 4 items are multiple choice questions with (1) correct answer. The final 2 items are rated on a Likert scale from 5 (Always) to 1 (Never). The score is calculated as the sum of (a) total correct answers to items 1-4 and (b) responses to items 5-6. The total score ranges from 2-14; higher scores indicate greater ability to recognize HER2-targeted ADC-related AEs and how they are managed.
- Patient HER2-Targeted ADC Related Side Effect Post-Test ScoreMonth 6
6 questions assessing ability to recognize HER2-targeted ADC-related AEs and how they are managed. 4 items are multiple choice questions with (1) correct answer. The final 2 items are rated on a Likert scale from 5 (Always) to 1 (Never). The score is calculated as the sum of (a) total correct answers to items 1-4 and (b) responses to items 5-6. The total score ranges from 2-14; higher scores indicate greater ability to recognize HER2-targeted ADC-related AEs and how they are managed.
- Clinician HER2-Targeted ADC Related Side Effect Pre-Test ScoreBaseline
7 questions assessing ability to recognize HER2-targeted ADC-related AEs and how they are managed. 5 items are multiple choice questions with (1) correct answer. The final 2 items are rated on a Likert scale from 5 (Always) to 1 (Never). The score is calculated as the sum of (a) total correct answers to items 1-5 and (b) responses to items 6-7. The total score ranges from 2-15; higher scores indicate greater ability to recognize HER2-targeted ADC-related AEs and how they are managed.
- Clinician HER2-Targeted ADC Related Side Effect Post-Test ScoreMonth 3
7 questions assessing ability to recognize HER2-targeted ADC-related AEs and how they are managed. 5 items are multiple choice questions with (1) correct answer. The final 2 items are rated on a Likert scale from 5 (Always) to 1 (Never). The score is calculated as the sum of (a) total correct answers to items 1-5 and (b) responses to items 6-7. The total score ranges from 2-15; higher scores indicate greater ability to recognize HER2-targeted ADC-related AEs and how they are managed.
- Clinician HER2-Targeted ADC Related Side Effect Post-Test ScoreMonth 6
7 questions assessing ability to recognize HER2-targeted ADC-related AEs and how they are managed. 5 items are multiple choice questions with (1) correct answer. The final 2 items are rated on a Likert scale from 5 (Always) to 1 (Never). The score is calculated as the sum of (a) total correct answers to items 1-5 and (b) responses to items 6-7. The total score ranges from 2-15; higher scores indicate greater ability to recognize HER2-targeted ADC-related AEs and how they are managed.